Evaluation of a Novel Auto Segmentation Algorithm for Normal Structure Delineation in Radiation Treatment Planning (NCT06200116)

🧪 Interventions in This Study

• Non-Interventional Study (OTHER)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (7 Sites)

• Mayo Clinic in Arizona — Scottsdale, Arizona
• Mayo Clinic in Florida — Jacksonville, Florida
• Mayo Clinic Health System in Albert Lea — Albert Lea, Minnesota
• Mayo Clinic Health Systems-Mankato — Mankato, Minnesota
• Mayo Clinic in Rochester — Rochester, Minnesota
• Mayo Clinic Health System-Eau Claire Clinic — Eau Claire, Wisconsin
• Mayo Clinic Health System-Franciscan Healthcare — La Crosse, Wisconsin

📞 Contact the Study Coordinator

Phone: (855) 776-0015

Email: mayocliniccancerstudies@mayo.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Malignant Solid Neoplasm

• Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) — Philadelphia, Pennsylvania
• Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors — Birmingham, Alabama
• Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) — Philadelphia, Pennsylvania
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial — Birmingham, Alabama
• Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial — Bethesda, Maryland
• Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) — Philadelphia, Pennsylvania

Explore by condition: All Malignant Solid Neoplasm clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.